Predictive impact of polymorphism of PNPLA3 on HCC development after interferon therapy in Japanese patients with chronic hepatitis C

详细信息    查看全文

• 作者：Yuki Moritou ; Fusao Ikeda ; Yoshiaki Iwasaki ; Nobuyuki Baba…
• 关键词：PNPLA3 ; Interferon ; HCC ; HCV
• 刊名：SpringerPlus
• 出版年：2013
• 出版时间：December 2013
• 年：2013
• 卷：2
• 期：1
• 全文大小：178KB
• 参考文献：Clark PJ, Thompson AJ, Zhu Q, Vock DM, Zhu M, Patel K, Harrison SA, Naggie S, Ge D, Tillmann HL, Urban TJ, Shianna K, Fellay J, Goodman Z, Noviello S, Pedicone LD, Afdhal N, Sulkowski M, Albrecht JK, Goldstein DB, McHutchison JG, Muir AJ: The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection. Dig Dis Sci 2012, 57:2213鈥?221.CrossRef
  Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ: Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994, 19:1513鈥?520.CrossRef
  Firpi RJ, Nelson DR: Current and future hepatitis C therapies. Arch Med Res 2007, 38:678鈥?90.CrossRef
  Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB, American Association for Study of Liver Diseases: An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011, 54:1433鈥?444.CrossRef
  Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB, American Association for Study of Liver D: An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011, 54:1433鈥?444.CrossRef
  He S, McPhaul C, Li JZ, Garuti R, Kinch LN, Grishin NV: A sequence variation (I148M) in PNPlA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem 2009, 285:6706鈥?715.CrossRef
  Ikeda F, Dansako H, Nishimura G, Mori K, Kawai Y, Ariumi Y: Amino acid substitutions of hepatitis C virus core protein are not associated with intracellular antiviral response to interferon-伪 in vitro. Liver Int 2010, 30:1324鈥?331.CrossRef
  Imai Y, Kawata S, Tamura S: Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Med 1998, 129:94鈥?9.CrossRef
  Kato N: Molecular virology of hepatitis C virus. Acta Med Okayama 2001, 55:133鈥?59.
  Kawaguchi T, Sumida Y, Umemura A, Matsuo K, Takahashi M, Takamura T, Yasui K, Saibara T, Hashimoto E, Kawanaka M, Watanabe S, Kawata S, Imai Y, Kokubo M, Shima T, Park H, Tanaka H, Tajima K, Yamada R, Matsuda F, Okanoue T, Japan Study Group of Nonalcoholic Fatty Liver Disease: Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS One 2012, 7:e38322.CrossRef
  Kotronen A, Johansson LE, Johansson LM, Roos C, Westerbacka J, Hamsten A: A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia 2009, 52:1056鈥?060.CrossRef
  Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N: Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012, 56:78鈥?4.CrossRef
  Makuuchi M, Kokudo N, Arii S: Clinical practice guidelines for hepatocellular carcinoma - the Japan society of hepatology 2009 update. Hepatol Res 2010, 40:2鈥?44.CrossRef
  Miyashita M, Ito T, Sakaki M, Kajiwara A, Nozawa H, Hiroishi K, Kobayashi M, Kumada H, Imawari M: Genetic polymorphism in cyclooxygenase-2 promoter affects hepatic inflammation and fibrosis in patients with chronic hepatitis C. J Viral Hepat 2012, 19:608鈥?14.CrossRef
  Nishiguchi S, Shiomi S, Nakatani S: Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001, 357:196鈥?97.CrossRef
  Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, Younossi Z, Albrecht J: Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003, 38:75鈥?5.CrossRef
  Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, Cohen JC, Hobbs HH: Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008, 40:1461鈥?465.CrossRef
  Takeuchi Y, Ikeda F, Moritou Y, Hagihara H, Yasunaka T, Kuwaki K, Miyake Y, Ohnishi H, Nakamura S, Shiraha H, Takaki A, Iwasaki Y, Nouso K, Yamamoto K: The impact of patatin-like phospholipase domain-containing protein 3 polymorphism on hepatocellular carcinoma prognosis. J Gastroenterol 2013, 48:405鈥?12.CrossRef
  Tr茅po E, Pradat P, Potthoff A, Momozawa Y, Quertinmont E, Gustot T, Lemmers A, Berthillon P, Amininejad L, Chevallier M, Schlu茅 J, Kreipe H, Devi猫re J, Manns M, Tr茅po C, Sninsky J, Wedemeyer H, Franchimont D, Moreno C: Impact of patatin-like phospholipase-3 (rs738409 C鈥?gt;鈥塆) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology 2011, 54:60鈥?9.CrossRef
  Valenti L, Alisi A, Galmozzi E, Bartuli A, Del Menico B, Alterio A, Dongiovanni P, Fargion S, Nobili V: I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology 2010, 52:1274鈥?280.CrossRef
  Valenti L, Rumi M, Galmozzi E, Aghemo A, Del Menico B, De Nicola S, Dongiovanni P, Maggioni M, Fracanzani AL, Rametta R, Colombo M, Fargion S: Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology 2011, 53:791鈥?99.CrossRef
  Valenti L, Aghemo A, St盲ttermayer AF, Maggioni P, De Nicola S, Motta BM, Rumi MG, Dongiovanni P, Ferenci P, Colombo M, Fargion S: Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin. Aliment Pharmacol Ther 2012, 35:1434鈥?442.CrossRef
  Yoshida H, Shiratori Y, Moriyama M: Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C. Ann Intern Med 1999, 131:174鈥?81.CrossRef
  Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, M眉llhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M, REALIZE Study Team: Telaprevir for retreatment of HCV infection. N Engl J Med 2011, 364:2417鈥?428.CrossRef
  
• 作者单位：Yuki Moritou (5)
  Fusao Ikeda (5) (5)
  Yoshiaki Iwasaki (5)
  Nobuyuki Baba (5)
  Kouichi Takaguchi (5)
  Tomonori Senoh (5)
  Takuya Nagano (5)
  Yasuto Takeuchi (5)
  Tetsuya Yasunaka (5)
  Hideki Ohnishi (5) (5)
  Yasuhiro Miyake (5)
  Akinobu Takaki (5)
  Kazuhiro Nouso (5) (5)
  Kazuhide Yamamoto (5) (5)
  
  5. Department of Internal Medicine, Kagawa Prefectural Central Hospital, Takamatsu, Japan
  
• 刊物类别：Science, general;
• 刊物主题：Science, general;
• 出版者：Springer International Publishing
• ISSN：2193-1801

文摘

The impact of single-nucleotide polymorphisms (SNP) of patatin-like phospholipase domain-containing protein 3 (PNPLA3) on development of hepatocellular carcinoma (HCC) is not clarified for Japanese patients with chronic hepatitis C. The present study investigated the associations of rs738409 PNPLA3 with HCC development after the antiviral therapy with peg-interferon and ribavirin for Japanese patients with hepatitis C virus serotype 1 and high viral load. Of the 271 patients enrolled in the study, 20 patients developed HCC, during a median follow-up period of 4.6 years. Multivariate analysis in the proportional hazards models revealed that sex, body mass index, platelet counts, and alpha feroprotein (AFP) had significant associations with HCC development (p鈥?鈥?.011, 0.029, 0.0002, and 0.046, respectively). Multivariate regression analysis revealed that PNPLA3 148 M was significantly associated with serum AFP level (p鈥?鈥?.032), other than body mass index, platelet count, and alanine aminotransferase (p鈥?鈥?.0006, 0.0002, and 0.037, respectively), and that serum AFP level was significantly associated with PNPLA3 148 M (p鈥?鈥?.017). Serum AFP level is an important factor in predicting HCC development after the antiviral therapy for Japanese patients with chronic hepatitis C, the mechanism of which might involve its significant associations with the SNP genotype of PNPLA3. Keywords PNPLA3 Interferon HCC HCV